Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Other Operating Expenses (2020 - 2023)

Ovid Therapeutics' Other Operating Expenses history spans 4 years, with the latest figure at -$1000.0 for Q1 2023.

  • For Q1 2023, Other Operating Expenses fell 100.48% year-over-year to -$1000.0; the TTM value through Dec 2023 reached -$1000.0, down 100.13%, while the annual FY2021 figure was -$45690.0, 111.56% down from the prior year.
  • Other Operating Expenses reached -$1000.0 in Q1 2023 per OVID's latest filing, down from $836085.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $836085.0 in Q3 2022 to a low of -$438260.0 in Q4 2020.
  • Average Other Operating Expenses over 4 years is $92476.6, with a median of $828.5 recorded in 2021.
  • The largest YoY upside for Other Operating Expenses was 31367.26% in 2022 against a maximum downside of 11188.32% in 2022.
  • A 4-year view of Other Operating Expenses shows it stood at -$438260.0 in 2020, then surged by 100.89% to $3903.0 in 2021, then surged by 21321.6% to $836085.0 in 2022, then plummeted by 100.12% to -$1000.0 in 2023.
  • Per Business Quant, the three most recent readings for OVID's Other Operating Expenses are -$1000.0 (Q1 2023), $836085.0 (Q3 2022), and -$284127.0 (Q2 2022).